# A Pilot Study of Recombinant Human Arginase 1 (rhArg1) in Patients With Relapsed or Refractory Leukemia or Lymphoma

> **NCT01551628** · PHASE1 · TERMINATED · sponsor: **Bio-Cancer Treatment International Limited** · enrollment: 1 (actual)

## Conditions studied

- Leukemia
- Lymphoma

## Interventions

- **DRUG:** Recombinant human arginase 1 Peg5000

## Key facts

- **NCT ID:** NCT01551628
- **Lead sponsor:** Bio-Cancer Treatment International Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-04
- **Primary completion:** 2013-05
- **Final completion:** 2013-05
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** slow patient recruitment
- **Last updated:** 2017-07-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01551628

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01551628, "A Pilot Study of Recombinant Human Arginase 1 (rhArg1) in Patients With Relapsed or Refractory Leukemia or Lymphoma". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT01551628. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*